Generic Medicine Info
Current or recent opioid addiction, acute opioid withdrawal symptoms, history of acute alcohol withdrawal syndrome. Severe hepatic and renal impairment. Concomitant use w/ opioid agonists (e.g. opioid analgesics, methadone) or partial agonists (e.g. buprenorphine).
Special Precautions
Patient w/ psychiatric comorbidity (e.g. major depressive disorder), history of seizure disorders. Intended for use only to patient w/ high drinking risk level, at least 2 wk after assessment. Mild or moderate renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Assess clinical status, alcohol dependence, level of alcohol consumption before initiation of therapy.
Adverse Reactions
Significant: Psychiatric symptoms, alcoholic psychosis, alcohol withdrawal symptoms. Nervous: Dizziness, insomnia, headache, sleep disorder, confusional state, restlessness, somnolence, tremor, attention disturbance, paraesthesia, hypoaesthesia, fatigue, asthenia, malaise, abnormal feeling, hallucinations, dissociation. CV: Tachycardia, palpitation. GI: Nausea, decreased appetite, vomiting, dry mouth, diarrhoea. Endocrine: Decreased libido, wt decreased. Musculoskeletal: Muscle spasms. Dermatologic: Hyperhidrosis.
Drug Interactions
Increased exposure w/ UGT2B7 enzyme inhibitors (e.g. diclofenac, fluconazole). Decreased exposure w/ UGT2B7 enzyme inducers (e.g. dexamethasone, phenobarbital).
ATC Classification
N07BB05 - nalmefene ; Belongs to the class of drugs used in the management of alcohol dependence.
Disclaimer: This information is independently developed by CIMS based on nalmefene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in